Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(4):258-260; doi:10.1093/jnci/djk072
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Veronesi, U.
Right arrow Articles by Decensi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veronesi, U.
Right arrow Articles by Decensi, A.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Tamoxifen: An Enduring Star

Umberto Veronesi, Patrick Maisonneuve, Andrea Decensi

Affiliations of authors: Scientific Director's Office (UV) and Divisions of Chemoprevention (AD) and Epidemiology and Biostatistics (PM), European Institute of Oncology, Milan, Italy; Division of Medical Oncology, Galliera Hospital, Genoa, Italy (AD)

Correspondence to: Umberto Veronesi, MD, Scientific Director's Office, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy (e-mail: umberto.veronesi@ieo.it).

The first 150 words of the full text of this article appear below.

In this issue of the Journal, two placebo-controlled studies (1,2) provide long-term results from trials of tamoxifen for the primary prevention of breast cancer in high-risk women. Cuzick et al. (1) expand on the first International Breast Cancer Intervention Study (IBIS-I), showing after a median follow-up of 8 years and 337 breast cancer events that tamoxifen statistically significantly reduces breast cancer by 29% with no attenuation of benefit after completion of the 5-year treatment schedule. Importantly, their data reveal a greater benefit from tamoxifen on estrogen receptor (ER)–positive disease in the follow-up period and an appreciable tapering of adverse events after the active treatment period, such that the risk–benefit ratio improved with longer follow-up. Similarly, Powles et al. (2) update the pioneering Royal Marsden trial after a median follow-up of 13 years and 186 events, reporting a non–statistically significant 22% reduction of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer—96-Month Follow-up of the Randomized IBIS-I Trial
Jack Cuzick, John F. Forbes, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, and Anthony Howell
J Natl Cancer Inst 2007 99: 272-282. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 257. [Extract] [Full Text] [PDF]

Press Release: Tamoxifen Yields Long-Term Reduction in Breast Cancer Risk
Liz Savage
J Natl Cancer Inst 2007 99: 257. [Extract] [Full Text]



This article has been cited by other articles:


Home page
 JCOHome page
G. Rondanina, M. Puntoni, G. Severi, C. Varricchio, A. Zunino, I. Feroce, B. Bonanni, and A. Decensi
Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users
J. Clin. Oncol., March 20, 2008; 26(9): 1537 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Fabian
Low-Dose Tamoxifen for Combination Hormone Replacement Therapy Users
J. Clin. Oncol., September 20, 2007; 25(27): 4162 - 4164.
[Full Text] [PDF]